EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Application of In‐House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital

Hatsuyo Takaoka, Hideki Terai iD, Kohei Nakamura iD, Takaaki Mizuno, Ryutaro Kawano, Katsura Emoto, Yutaka Kurebayashi, Nao Takada, Kenta Hamabe, Kazuhito Horie, Akihiko Ogata, Katsuhito Kinoshita und 14 weitere

Cancer Science · 2025-10 · 116 (10) · 2819-2830

DOI: 10.1111/cas.70168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 04.08.2025. Verfasst von Hatsuyo Takaoka und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Lung Neoplasms, Thoracic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comprehensive genomic profiling (CGP) is useful for optimizing targeted therapy and immunotherapy strategies for thoracic malignancies. This study aimed to evaluate the clinical utility and diagnostic complementarity of the in‐house sequencing platform Rapid‐Neo. We retrospectively analyzed 110 patients with thoracic malignancies who underwent Rapid‐Neo testing. The baseline characteristics, sequencing results, concordance with companion diagnostics (CDx), and clinical outcomes were assessed. Of 110 patients, 100 (90.9%) had primary lung cancer. Rapid‐Neo identified at least one genomic alteration in 99.1% of cases and well‐established driver alterations in 66.0% of lung cancer cases. TMB‐high and MSI‐high statuses were observed in 9.0% and 2.0% of cases, respectively. Among the 90 cases with prior CDx, Rapid‐Neo identified driver alterations in 10.0% of the cases, including EGFR , KRAS , MET , RET , and ERBB2 , suggesting its potential to overcome the limitations of conventional CDx tests. High concordance (96.8%) was observed between the Rapid‐Neo and CDx results, finally. In EGFR‐mutant lung adenocarcinoma, high tumor mutation burden (TMB) was associated with a significantly shorter progression‐free survival (PFS) after EGFR‐TKI therapy (HR = 2.58, p = 0.018) and remained an independent prognostic factor in multivariate analysis. Furthermore, among patients receiving immune checkpoint inhibitors (ICIs), favorable genomic markers such as TMB‐high or MSI‐high were associated with prolonged PFS. Rapid‐Neo demonstrated high sensitivity and concordance with CDx, while also identifying actionable driver alterations missed by the initial CDx. Moreover, the genomic markers identified by Rapid‐Neo may provide predictive values for both targeted therapy and immunotherapy responses, supporting their integration into routine clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorLung NeoplasmsThoracic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedGenomicsJapanMutationPrognosisRetrospective StudiesEast Asian People

Stichwörter der Autor:innen

TMBcompanion dianosticsdriver oncogenegenomic profilinglung cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan.
  • Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
  • Center for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.
  • Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Department of Respiratory Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

ORCID-Profile: Hideki Terai, Kohei Nakamura

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Takaoka, H., Terai, H., Nakamura, K., Mizuno, T., Kawano, R., Emoto, K., Kurebayashi, Y., Takada, N., Hamabe, K., Horie, K., Ogata, A., Kinoshita, K., Shigematsu, L., Ito, F., Okada, M., Fukushima, T., Nukaga, S., Tani, T., Ohgino, K., …, & Fukunaga, K. (2025). Clinical Application of In‐House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital. Cancer Science, 116(10), 2819-2830. https://doi.org/10.1111/cas.70168

Vancouver

Takaoka H, Terai H, Nakamura K, Mizuno T, Kawano R, Emoto K, et al. Clinical Application of In‐House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital. Cancer Science. 2025;116(10):2819-2830. doi:10.1111/cas.70168

BibTeX
@article{Takaoka2025,
  author = {Takaoka, Hatsuyo and Terai, Hideki and Nakamura, Kohei and Mizuno, Takaaki and Kawano, Ryutaro and Emoto, Katsura and Kurebayashi, Yutaka and Takada, Nao and Hamabe, Kenta and Horie, Kazuhito and Ogata, Akihiko and Kinoshita, Katsuhito and Shigematsu, Lisa and Ito, Fumimaro and Okada, Masahiko and Fukushima, Takahiro and Nukaga, Shigenari and Tani, Testuo and Ohgino, Keiko and Kaseda, Kaoru and Ikemura, Shinnosuke and Yasuda, Hiroyuki and Asakura, Keisuke and Okita, Hajime and Nishihara, Hiroshi and Fukunaga, Koichi},
  title = {Clinical Application of In‐House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {10},
  pages = {2819--2830},
  doi = {10.1111/cas.70168}
}
Kostenlos starten →